Stage IV Breast Cancer
202
5
12
129
Key Insights
Highlights
Success Rate
75% trial completion
Published Results
84 trials with published results (42%)
Research Maturity
129 completed trials (64% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
20.8%
42 terminated out of 202 trials
75.4%
-11.1% vs benchmark
4%
8 trials in Phase 3/4
65%
84 of 129 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 129 completed trials
Clinical Trials (202)
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer
Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
Window of Opportunity Study Targeting the Inflammatory Milieu
Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer
Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer
Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer
Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Mindfulness-Based Stress Reduction in Helping Participants With Metastatic Breast Cancer